AXIM

Healthcare Biotechnology

AXIM Biotechnologies, Inc.

$0.00

-0.00 -25.00% today

Price History

Not enough data

Key Stats

Market Cap

1.05M

Avg Volume

378,762

52W High

$0.03

52W Low

$0.00

Div. Yield

0.0%

Valuation

P/B Ratio

-0.09

P/S Ratio

11.30

EV/EBITDA

-4.15

EV/Revenue

84.15

Margins

Gross Margin 98.1%

Operating Margin (3257.9%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

76.0%

Return on Assets

(36.3%)

Liquidity & Leverage

Current Ratio

0.00

Quick Ratio

0.00

Total Cash

6,044

Total Debt

6.78M

About

AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.